Curetis
OpGen to Execute 1-for-10 Reverse Stock Split
The reverse stock split is intended to bring the firm back into compliance with the Nasdaq's minimum bid price listing requirement of $1.00 per share.
OpGen Sells Customer Contracts, Installed MDx Instrument Base for $218K
The contracts and instrument base was acquired by Singapore-based Camtech, which had previously acquired OpGen's Curetis subsidiary during insolvency proceedings.
OpGen Subsidiaries Curetis, Ares Genetics File for Bankruptcy
The bankruptcy proceedings come after OpGen's unsuccessful attempts to sell Curetis and Ares Genetics or their assets.
Curetis, FIND Extend Antimicrobial Resistance Research Collaboration
The extended partnership covers the development of an AMR assay, a cartridge for the Unyvero A30 platform, and a software plug-in.
In Brief This Week: Yourgene Health, Epigenomics, Bionano Genomics, Diatech Pharmacogenetics, More
News items for the week of April 24, 2023.
Sep 20, 2022
FIND, Curetis Ink R&D Collaboration Agreement
Nov 6, 2020
Aug 20, 2020
OpGen Nabs CE-IVD Mark for SARS-CoV-2 Kit
Aug 12, 2020
OpGen Q2 Revenues Climb 20 Percent
May 7, 2020
OpGen Q1 Revenues Drop 38 Percent
Apr 14, 2020
OpGen Q1 Preliminary Revenues Down 38 Percent
Mar 24, 2020
OpGen Fourth Quarter Revenues Increase 8 Percent
Feb 20, 2020
Curetis Preliminary 2019 Revenues Up 64 Percent
Feb 12, 2020